Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry
Main finding · DMARD escalation at the 12-month visitResult — go to the resultOdds ratio 2.62 95% CI 1.33–5.18Authors' conclusion
In a large multicenter registry of US patients with JIA, DMARD escalation at the 12-month visit was uncommon overall, even for those with persistent moderate/high disease activity.
Study context
- Population
- Patients with non-systemic juvenile idiopathic arthritis (JIA) in the CARRA Registry with complete clinical Juvenile Arthritis Disease Activity Scores (cJADAS) at 6- and 12-month registry visits, US
- Participants
- 2,956 patients
- Exposure
- cJADAS patterns across 6- and 12-month registry visits
- Outcome
- DMARD escalation at the 12-month visit
- Follow-up
- 12-month visit
Methodological detailsmulticentre, multivariable logistic regression
- Multicentre
- Multivariable logistic regression
Main finding
As reported in the abstract
Odds ratio
2.62
95% CI 1.33–5.18
By group
Persistent moderate/high
15%
Flaring
OR 2.62 (95% CI 1.33–5.18)
- Disease modifying anti-rheumatic drug (DMARD) escalation at the 12-month visit, all patients
- 10%
- Associated with DMARD escalation between the 6- and 12-month visits, OR
- 1.86 (1.40-2.49) (95% CI)
- Associated with morning stiffness > 60 min
- 4.98 (3.00-8.27) (95% CI)
- Age 15-19 years less likely to escalate, OR
- 0.61 (0.38-0.97) (95% CI)
Observational data: associations, not effects.
Further findings
Distribution of cJADAS patterns across paired visits
Original publication
Disease activity at two consecutive registry visits and subsequent medication escalation for patients with juvenile idiopathic arthritis in the CARRA registry. Pediatr Rheumatol Online J. Published 22 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →